Retrovirus Epidemiology Donor Study-II (REDS-II)
NCT00097006 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2016-04-15
Summary
To conduct epidemiological, laboratory, and survey research on volunteer blood donors within the United States to ensure the safety and availability of the United States' blood supply.
Conditions
- Acquired Immunodeficiency Syndrome
- Blood Donors
- Blood Transfusion
- HIV Infections
- HIV-1
- HIV-2
- HTLV-I
- HTLV-II
- Retroviridae Infections
- Hepatitis, Viral, Human
- Hepatitis B
- Hepacivirus
- West Nile Virus
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Principal Investigators
-
Michael Busch · Vitalant Research Institute
-
Jerome Gottschall · Blood Center of Southeastern Wisconsin, Inc.
-
Christopher Hillyer · Emory University
-
Ram Kakaiya · Institute for Transfusion Medicine
-
Edward Murphy · University of California, San Francisco
-
Jorge Rios · American Red Cross Blood Services, New England Region
-
Ronald Sacher · University of Cincinnati
-
George Schreiber · Westat, Inc.
Eligibility
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-09-30
- Primary Completion
- 2009-09-30
- Completion
- 2009-09-30
More Related Trials
-
Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS
NCT04333459 ·Status: COMPLETED ·Phase: PHASE2
-
Immunology of Ebola Vaccine
NCT06100913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
NCT01782300 ·Status: COMPLETED ·Phase: PHASE1
-
Ebola and Marburg Virus Vaccines
NCT00605514 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
NCT02186626 ·Status: COMPLETED ·Phase: PHASE1
-
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
NCT02723773 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
NCT05142514 ·Status: COMPLETED ·Phase: PHASE2
-
Yellow Fever Human Infection Model With YF-17D
NCT05901454 ·Status: UNKNOWN ·Phase: NA
-
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
NCT05921903 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
NCT02508194 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine
NCT00920517 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults
NCT02289820 ·Status: COMPLETED ·Phase: PHASE1
-
Experimental Ebola Vaccine Trial
NCT00072605 ·Status: COMPLETED ·Phase: PHASE1
-
Experimental Vaccine for Prevention of Ebola Virus Infection
NCT00374309 ·Status: COMPLETED ·Phase: PHASE1
-
dMAbs for Prevention of COVID-19
NCT05293249 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
NCT00350337 ·Status: COMPLETED ·Phase: PHASE2
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
NCT03037164 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
NCT07205796 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
NCT02298179 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers
NCT02670187 ·Status: COMPLETED ·Phase: PHASE1
-
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
NCT02254421 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
NCT00239577 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557
NCT00578682 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
NCT06911320 ·Status: RECRUITING ·Phase: PHASE1
-
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
NCT02254408 ·Status: COMPLETED ·Phase: PHASE2